GLP-1 weight-loss drugs: How profit-driven healthcare obscures systemic eating disorder risks and marginalises patient safety
Original framing: “What’s the true risk for eating disorders with GLP-1s?” — STAT News
Black, Indigenous, and disabled communities face higher rates of disordered eating due to systemic weight stigma and healthcare discrimination, yet are least likely to access GLP-1s or receive proper screening. Trans and non-binary individuals report GLP-1s being prescribed without consideration of gender dysphoria or trauma-related eating patterns. Low-income patients are targeted by pharmaceutical marketing, while uninsured individuals are excluded from these treatments entirely. The narrative’s focus on 'risk' ignores how marginalised patients are already navigating a healthcare system that pathologises their bodies.
The GLP-1 narrative exemplifies how capitalism and colonial medicine converge to medicalise normal human diversity, framing body size as a pathology while obscuring the profit motives behind its 'treatment.
' The historical commodification of thinness, coupled with regulatory capture and pharmaceutical marketing, has created a perfect storm where patients are both the targets and casualties of a system that prioritises short-term profits over long-term wellbeing. Indigenous and marginalised voices reveal that eating disorders are not merely individual failures but symptoms of deeper cultural and structural violence—whether through the erasure of traditional foodways, the racialisation of body standards, or the medicalisation of gender nonconformity. The 'trickster' lens exposes the absurdity of selling a drug to 'fix' a problem the same industry exacerbates, while future modelling warns of a dystopian healthcare landscape where GLP-1s become the default 'solution' to a problem rooted in systemic inequity. True reform requires dismantling the weight-centric paradigm, centring community-led care, and redefining health as holistic—not reducible to a number on a scale or a pill in a bottle.